X
skip to main content
Logo

Canadian Colorectal Cancer Consortium (C4)

Joining Canadian efforts for reducing colorectal cancer incidence and mortality

Colorectal cancer (CRC) is the second leading cause of cancer death among Canadians. CRC can be detected at early stages through colonoscopic surveillance and identifying those at increased risk is of utmost importance. The more advanced the disease at the time of diagnosis, the greater the risk of metastatic disease and resistance to treatment. The strong relationship between stage and prognosis, coupled with the response to novel and current therapies highlight the importance of integrating two major axes in the Canadian Colorectal Cancer Consortium (C4):

Screening Axis

Led by Dr. Steven Gallinger, Senior Investigator at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital and Head of Hepatobiliary/Pancreatic Surgical Oncology at the University Health Network.

  • Accurately stratify patients with incident CRC in high volume centres according to familial risk:
    • Implement institutional tumour screening for Lynch Syndrome
  • Provide data on clinical presentation, frequency, phenotypes and genotypes of Lynch syndrome in a Canadian context
  • Identify high-risk non-Lynch syndrome families
    • Identify new Familial CRC Type X genes
    • Discover novel genetic factors causing high-risk CRC.
  • Understand and improve strategies to implement appropriate screening in at-risk family members

Therapeutic Axis

Led by Dr. Gerald Batist, Director of the Segal Cancer Centre and the Department of Oncology at the Jewish General Hospital in Montreal and Co-Director of the Quebec-Clinical Research Organization in Cancer.

  • Enhance individualization of cancer medicine and create opportunities for approaches to prevent, circumvent and/or avoid clinical resistance in CRC
  • Merge molecular pathology, clinical, multi-omics and functional validation data to discover signatures of resistance
  • Create a unique bio-repository of metastatic biopsies and serial blood samples collected in a defined clinical context, amenable to multi-dimensional analysis
  • Facilitate integration of biomarkers into multiplexed diagnostic kits that guide therapy decisions

The C4 is looking for public and private organizations with the same mission of reducing the impact of CRC on the population using innovative research approaches to enhance screening and treatment outcomes.

Back to Top